» Articles » PMID: 30157398

Type 2 Poliovirus Detection After Global Withdrawal of Trivalent Oral Vaccine

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2018 Aug 30
PMID 30157398
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mass campaigns with oral poliovirus vaccine (OPV) have brought the world close to the eradication of wild poliovirus. However, to complete eradication, OPV must itself be withdrawn to prevent outbreaks of vaccine-derived poliovirus (VDPV). Synchronized global withdrawal of OPV began with serotype 2 OPV (OPV2) in April 2016, which presented the first test of the feasibility of eradicating all polioviruses.

Methods: We analyzed global surveillance data on the detection of serotype 2 Sabin vaccine (Sabin-2) poliovirus and serotype 2 vaccine-derived poliovirus (VDPV2, defined as vaccine strains that are at least 0.6% divergent from Sabin-2 poliovirus in the viral protein 1 genomic region) in stool samples from 495,035 children with acute flaccid paralysis in 118 countries and in 8528 sewage samples from four countries at high risk for transmission; the samples were collected from January 1, 2013, through July 11, 2018. We used Bayesian spatiotemporal smoothing and logistic regression to identify and map risk factors for persistent detection of Sabin-2 poliovirus and VDPV2.

Results: The prevalence of Sabin-2 poliovirus in stool samples declined from 3.9% (95% confidence interval [CI], 3.5 to 4.3) at the time of OPV2 withdrawal to 0.2% (95% CI, 0.1 to 2.7) at 2 months after withdrawal, and the detection rate in sewage samples declined from 71.0% (95% CI, 61.0 to 80.0) to 13.0% (95% CI, 8.0 to 20.0) during the same period. However, 12 months after OPV2 withdrawal, Sabin-2 poliovirus continued to be detected in stool samples (<0.1%; 95% CI, <0.1 to 0.1) and sewage samples (8.0%; 95% CI, 5.0 to 13.0) because of the use of OPV2 in response to VDPV2 outbreaks. Nine outbreaks were reported after OPV2 withdrawal and were associated with low coverage of routine immunization (odds ratio, 1.64 [95% CI, 1.14 to 2.54] per 10% absolute decrease) and low levels of population immunity (odds ratio, 2.60 [95% CI, 1.35 to 5.59] per 10% absolute decrease) within affected countries.

Conclusions: High population immunity has facilitated the decline in the prevalence of Sabin-2 poliovirus after OPV2 withdrawal and restricted the circulation of VDPV2 to areas known to be at high risk for transmission. The prevention of VDPV2 outbreaks in these known areas before the accumulation of substantial cohorts of children susceptible to type 2 poliovirus remains a high priority. (Funded by the Bill and Melinda Gates Foundation and the World Health Organization.).

Citing Articles

Development of RT-PCR Assays for Simple Detection and Identification of Sabin Virus Contaminants in the Novel Oral Poliovirus Vaccines.

Singh O, Manukyan H, Tritama E, Lee S, Weir J, Laassri M Vaccines (Basel). 2025; 13(1).

PMID: 39852854 PMC: 11768561. DOI: 10.3390/vaccines13010075.


Polio eradication: A perspective from the UK.

Simons H, Patel D New Microbes New Infect. 2024; 62:101490.

PMID: 39403552 PMC: 11472624. DOI: 10.1016/j.nmni.2024.101490.


Safety and Immunogenicity of Trivalent Oral Polio Vaccine in Vaccinated Children and Vaccine-Naïve Infants: A Phase 4 Study.

Mejia L, Mendez L, Ruttimann R, Gast C, Bandyopadhyay A Vaccines (Basel). 2024; 12(9).

PMID: 39339985 PMC: 11436059. DOI: 10.3390/vaccines12090953.


Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine.

Xu J, Liu Y, Qiu W, Li W, Hu X, Li X BMC Infect Dis. 2024; 24(1):535.

PMID: 38807038 PMC: 11131326. DOI: 10.1186/s12879-024-09389-8.


Modeling the spread of circulating vaccine-derived poliovirus type 2 outbreaks and interventions: A case study of Nigeria.

Sun Y, Keskinocak P, Steimle L, Kovacs S, Wassilak S Vaccine X. 2024; 18:100476.

PMID: 38617838 PMC: 11011220. DOI: 10.1016/j.jvacx.2024.100476.


References
1.
Pons-Salort M, Molodecky N, OReilly K, Wadood M, Safdar R, Etsano A . Population Immunity against Serotype-2 Poliomyelitis Leading up to the Global Withdrawal of the Oral Poliovirus Vaccine: Spatio-temporal Modelling of Surveillance Data. PLoS Med. 2016; 13(10):e1002140. PMC: 5049753. DOI: 10.1371/journal.pmed.1002140. View

2.
Kew O, Sutter R, de Gourville E, Dowdle W, Pallansch M . Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005; 59:587-635. DOI: 10.1146/annurev.micro.58.030603.123625. View

3.
Asghar H, Diop O, Weldegebriel G, Malik F, Shetty S, El Bassioni L . Environmental surveillance for polioviruses in the Global Polio Eradication Initiative. J Infect Dis. 2014; 210 Suppl 1:S294-303. PMC: 10578309. DOI: 10.1093/infdis/jiu384. View

4.
Sutter R, Platt L, Mach O, Jafari H, Aylward R . The new polio eradication end game: rationale and supporting evidence. J Infect Dis. 2014; 210 Suppl 1:S434-8. DOI: 10.1093/infdis/jiu222. View

5.
. Apparent global interruption of wild poliovirus type 2 transmission. MMWR Morb Mortal Wkly Rep. 2001; 50(12):222-4. View